



## Original Research

# Survival and mortality rates of Wilms tumour in Southern and Eastern European countries: Socioeconomic differentials compared with the United States of America



Dimitrios Doganis <sup>a,b,1</sup>, Paraskevi Panagopoulou <sup>a,1</sup>, Athanasios Tragiannidis <sup>a,c</sup>, Theodoros Vichos <sup>a</sup>, Maria Moschovi <sup>d</sup>, Sofia Polychronopoulou <sup>e</sup>, Eftimia Rigatou <sup>e</sup>, Eugenia Papakonstantinou <sup>f</sup>, Eftichia Stiakaki <sup>g</sup>, Helen Dana <sup>h</sup>, Panagiota Bouka <sup>a</sup>, Luis Antunes <sup>i</sup>, Joana Bastos <sup>j</sup>, Daniela Coza <sup>k</sup>, Anna Demetriou <sup>l</sup>, Domenic Agius <sup>m</sup>, Sultan Eser <sup>n</sup>, Anton Ryzhov <sup>o</sup>, Mario Sekerija <sup>p,q</sup>, Maciej Trojanowski <sup>r</sup>, Tina Zagar <sup>s</sup>, Anna Zborovskaya <sup>t</sup>, Snezana Zivkovic Perisic <sup>u</sup>, Katerina Strantzia <sup>v</sup>, Nick Dessypris <sup>a</sup>, Theodora Psaltopoulou <sup>a</sup>, Eleni Th Petridou <sup>a,w,\*</sup>

<sup>a</sup> Department of Hygiene, Epidemiology and Medical Statistics, School of Medicine, National and Kapodistrian University of Athens, Greece

<sup>b</sup> Oncology Department, “P & A Kyriakou” Children’s Hospital, Athens, Greece

<sup>c</sup> Hematology-Oncology Unit, 2nd Pediatric Department, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece

<sup>d</sup> Pediatric Hematology-Oncology Unit, First Department of Pediatrics, University of Athens, “Agia Sofia” Children’s Hospital, Athens, Greece

<sup>e</sup> Department of Pediatric Hematology-Oncology, “Agia Sofia” Children’s Hospital, Athens, Greece

<sup>f</sup> Department of Pediatric Hematology and Oncology, Hippokraton Hospital, Thessaloniki, Greece

<sup>g</sup> Department of Pediatric Hematology-Oncology, University of Crete, Heraklion, Greece

<sup>h</sup> Pediatric Hematology-Oncology Department, “Mitera” Children’s Hospital, Athens, Greece

<sup>i</sup> North Region Cancer Registry of Portugal (RORENO), Portuguese Institute of Oncology, Porto, Portugal

<sup>j</sup> Registo Oncológico Regional Do Centro (ROR-Centro), Instituto Português de Oncologia de Coimbra Francisco Gentil, E.P.E., Coimbra, Portugal

<sup>k</sup> Cluj Regional Cancer Registry, The Oncology Institute “Prof. Dr. Ion Chiricuță”, Cluj-Napoca, Romania

<sup>l</sup> Health Monitoring Unit, Ministry of Health, Nicosia, Cyprus

<sup>m</sup> Malta National Cancer Registry, Department for Policy in Health - Health Information and Research, Pieta, Malta

<sup>n</sup> Izmir Cancer Registry, Izmir Hub, Izmir and Hacettepe, University Institute of Public Health, Ankara, Turkey

<sup>o</sup> National Cancer Registry of Ukraine, National Institute of Cancer, Kiev, Ukraine & Taras Shevchenko National University of Kyiv, Ukraine

\* Corresponding author: Department of Hygiene, Epidemiology and Medical Statistics Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Str, Athens, 11527, Greece. Fax: +30 210 7462105.

E-mail address: [epetrid@med.uoa.gr](mailto:epetrid@med.uoa.gr) (E.T. Petridou).

<sup>1</sup> Equal contribution.

<https://doi.org/10.1016/j.ejca.2018.06.012>

0959-8049/© 2018 Elsevier Ltd. All rights reserved.

<sup>p</sup> Croatian Institute of Public Health, Croatian National Cancer Registry, Zagreb, Croatia

<sup>q</sup> Andrija Štampar School of Public Health, School of Medicine, University of Zagreb, Croatia

<sup>r</sup> Greater Poland Cancer Registry, Greater Poland Cancer Center, Poznan, Poland

<sup>s</sup> Cancer Registry of Slovenia, Institute of Oncology Ljubljana, Ljubljana, Slovenia

<sup>t</sup> Belarusian Research Center for Paediatric Oncology, Haematology and Immunology, Childhood Cancer Subregistry of Belarus, Minsk, Belarus

<sup>u</sup> Institute of Public Health of Serbia, Central Serbia Cancer Registry, Dr Subotica 5, 11000, Belgrade Serbia

<sup>v</sup> Pathology Laboratory, “P & A. Kyriakou” Children’s Hospital, Athens, Greece

<sup>w</sup> Clinical Epidemiology Unit, Department of Medicine, Karolinska Institute, Stockholm, Sweden

Received 26 February 2018; received in revised form 4 June 2018; accepted 11 June 2018

## KEYWORDS

Wilms tumour;  
Survival;  
Mortality trends;  
Urbanisation;  
Sociodemographic  
differentials;  
Healthcare access

**Abstract Background:** Despite recent therapeutic advancements, Wilms tumour (WT) presents remarkable survival variations. We explored mortality and survival patterns for children (0–14 years) with WT in 12 Southern and Eastern European (SEE) countries in comparison with the United States of America (USA).

**Methods:** A total of 3966 WT cases (0–14 years) were registered by a network of SEE childhood cancer registries (N:1723) during available registration periods circa 1990–2016 and surveillance, epidemiology, and end results program (SEER) (N:2243; 1990–2012); mortality data were provided by the respective national statistical services. Kaplan–Meier curves and Cox proportional hazards models were used to assess the role of age, sex, year of diagnosis, urbanisation and Human Development Index (HDI) on overall survival (OS).

**Results:** Persisting regional variations shape an overall 78% 5-year OS in the participating SEE countries, lagging behind the USA figure (92%,  $p=0.001$ ) and also reflected by higher SEE mortality rates. Worth mentioning is the gradually escalating OS in SEE (hazard ratio [HR]<sub>5-year increment</sub>:0.67, 95% confidence interval [CI]:0.60, 0.75) vs. a non-significant 10% improvement in the SEER data, which had a high starting value. OS differentials [two-fold less favourable among children aged 10–14 years, boys and those living in rural SEE areas (HR:1.37; CI:1.10–1.71) or countries with inferior HDI (2–3-fold)] were minimal in the USA.

**Conclusions:** Children with WT residing in SEE countries do not equally enjoy the substantial survival gains, especially for those living in rural areas and in lower HDI countries. Noteworthy are steep and sizeable survival gains in SEE along with the newly presented Greek data pointing to achievable survival goals in SEE despite the financial crisis.

© 2018 Elsevier Ltd. All rights reserved.

## 1. Introduction

Wilms tumour (WT) or nephroblastoma is an embryonal kidney tumour, slightly more common among girls representing around 6% of childhood (0–14 years) cancer cases [1,2]. Incidence rates in Europe (8.2/million) present significant regional differences (Automated Childhood Cancer Information System [ACCIS]) [1] being higher (9.2/million) in the participating Southern and Eastern European (SEE) countries [3].

Management of children with WT represents a success story in paediatric oncology [1]; over 90% of cases are successfully treated [4,5] in developed countries, and the challenge has lately shifted towards minimising short- and long-term toxicity [6]. Conversely, survival rates are still relatively poor in most developing countries [7].

In the present study, we aimed to calculate WT survival and mortality patterns during the last decades in 12 SEE countries, including Greece where the Nationwide Registry for Childhood Hematological Malignancies has been extended to include solid tumours. The role of gender and age, place of residence and Human Development Index (HDI) on overall survival (OS) was also examined in comparison with figures in the United States of America (USA), a country with higher HDI.

## 2. Materials and methods

An informal network initiated in the context of EUROpe against Cancer: Optimisation of the Use of Registries for Scientific Excellence in research project and comprising 12 population-based cancer registries in 11 SEE countries (Belarus, Croatia, Cyprus, Greece,

Download English Version:

<https://daneshyari.com/en/article/8439295>

Download Persian Version:

<https://daneshyari.com/article/8439295>

[Daneshyari.com](https://daneshyari.com)